Literature DB >> 18926090

Ovarian cancer biomarkers: current options and future promise.

Christine M Coticchia1, Jiang Yang, Marsha A Moses.   

Abstract

As more effective, less toxic cancer drugs reach patients, the need for accurate and reliable cancer diagnostics and prognostics has become widely appreciated. Nowhere is this need more dire than in ovarian cancer; here most women are diagnosed late in disease progression. The ability to sensitively and specifically predict the presence of early disease and its status, stage, and associated therapeutic efficacy has the potential to revolutionize ovarian cancer detection and treatment. This article reviews current ovarian cancer diagnostics and prognostics and potential biomarkers that are being studied and validated. Some of the most recent molecular approaches being used to identify genes and proteins are presented, which may represent the next generation of ovarian cancer diagnostics and prognostics.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18926090      PMCID: PMC3381792          DOI: 10.6004/jnccn.2008.0059

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN: 1540-1405            Impact factor:   11.908


  74 in total

1.  microRNAs exhibit high frequency genomic alterations in human cancer.

Authors:  Lin Zhang; Jia Huang; Nuo Yang; Joel Greshock; Molly S Megraw; Antonis Giannakakis; Shun Liang; Tara L Naylor; Andrea Barchetti; Michelle R Ward; George Yao; Angelica Medina; Ann O'brien-Jenkins; Dionyssios Katsaros; Artemis Hatzigeorgiou; Phyllis A Gimotty; Barbara L Weber; George Coukos
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-05       Impact factor: 11.205

2.  Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer.

Authors:  Lukas A Hefler; Robert Zeillinger; Christoph Grimm; Anil K Sood; Wen Fang Cheng; Angiolo Gadducci; Clemens B Tempfer; Alexander Reinthaller
Journal:  Gynecol Oncol       Date:  2006-06-05       Impact factor: 5.482

3.  Osteopontin in metastatic lesions as a prognostic marker in ovarian cancers.

Authors:  Li Hong Bao; Hideki Sakaguchi; Jiro Fujimoto; Teruhiko Tamaya
Journal:  J Biomed Sci       Date:  2007-01-13       Impact factor: 8.410

4.  Evaluation of apolipoprotein A1 and posttranslationally modified forms of transthyretin as biomarkers for ovarian cancer detection in an independent study population.

Authors:  Lee E Moore; Eric T Fung; Marielena McGuire; Charles C Rabkin; Annette Molinaro; Zheng Wang; Fujun Zhang; Jing Wang; Christine Yip; Xiao-Ying Meng; Ruth M Pfeiffer
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-09       Impact factor: 4.254

5.  MicroRNA signatures in human ovarian cancer.

Authors:  Marilena V Iorio; Rosa Visone; Gianpiero Di Leva; Valentina Donati; Fabio Petrocca; Patrizia Casalini; Cristian Taccioli; Stefano Volinia; Chang-Gong Liu; Hansjuerg Alder; George A Calin; Sylvie Ménard; Carlo M Croce
Journal:  Cancer Res       Date:  2007-09-15       Impact factor: 12.701

Review 6.  MicroRNA expression and function in cancer.

Authors:  Ramiro Garzon; Muller Fabbri; Amelia Cimmino; George A Calin; Carlo M Croce
Journal:  Trends Mol Med       Date:  2006-10-30       Impact factor: 11.951

7.  Human kallikrein 8 protein is a favorable prognostic marker in ovarian cancer.

Authors:  Carla A Borgoño; Tadaaki Kishi; Andreas Scorilas; Nadia Harbeck; Julia Dorn; Barbara Schmalfeldt; Manfred Schmitt; Eleftherios P Diamandis
Journal:  Clin Cancer Res       Date:  2006-03-01       Impact factor: 12.531

8.  Whole genome oligonucleotide-based array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomas.

Authors:  Michael J Birrer; Michael E Johnson; Ke Hao; Kwong-Kwok Wong; Dong-Choon Park; Aaron Bell; William R Welch; Ross S Berkowitz; Samuel C Mok
Journal:  J Clin Oncol       Date:  2007-06-01       Impact factor: 44.544

9.  Matrix metalloproteinase-2 (MMP-2) and -9 (MMP-9) and their tissue inhibitors (TIMP-1 and TIMP-2) in differential diagnosis between low malignant potential (LMP) and malignant ovarian tumours.

Authors:  Milla Määtta; Anne Talvensaari-Mattila; Taina Turpeenniemi-Hujanen; Markku Santala
Journal:  Anticancer Res       Date:  2007 Jul-Aug       Impact factor: 2.480

10.  Let-7 expression defines two differentiation stages of cancer.

Authors:  Scott Shell; Sun-Mi Park; Amir Reza Radjabi; Robert Schickel; Emily O Kistner; David A Jewell; Christine Feig; Ernst Lengyel; Marcus E Peter
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-28       Impact factor: 11.205

View more
  21 in total

Review 1.  Protein biomarkers of ovarian cancer: the forest and the trees.

Authors:  Brian M Nolen; Anna E Lokshin
Journal:  Future Oncol       Date:  2012-01       Impact factor: 3.404

2.  Programmable bio-nano-chip systems for serum CA125 quantification: toward ovarian cancer diagnostics at the point-of-care.

Authors:  Archana Raamanathan; Glennon W Simmons; Nicolaos Christodoulides; Pierre N Floriano; Wieslaw B Furmaga; Spencer W Redding; Karen H Lu; Robert C Bast; John T McDevitt
Journal:  Cancer Prev Res (Phila)       Date:  2012-04-09

3.  Upregulated microRNA-224 promotes ovarian cancer cell proliferation by targeting KLLN.

Authors:  Ke Hu; Meng Liang
Journal:  In Vitro Cell Dev Biol Anim       Date:  2016-09-23       Impact factor: 2.416

4.  Current and Futuristic Roadmap of Ovarian Cancer Management: An Overview.

Authors:  Orlandric Miree; Sanjeev Kumar Srivastava; Santanu Dasgupta; Seema Singh; Rodney Rocconi; Ajay Pratap Singh
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

5.  Three-dimensional ovarian organ culture as a tool to study normal ovarian surface epithelial wound repair.

Authors:  Kevin S Jackson; Kari Inoue; David A Davis; Tyvette S Hilliard; Joanna E Burdette
Journal:  Endocrinology       Date:  2009-05-07       Impact factor: 4.736

6.  HtrA3 Is Downregulated in Cancer Cell Lines and Significantly Reduced in Primary Serous and Granulosa Cell Ovarian Tumors.

Authors:  Harmeet Singh; Ying Li; Peter J Fuller; Craig Harrison; Jyothsna Rao; Andrew N Stephens; Guiying Nie
Journal:  J Cancer       Date:  2013-02-01       Impact factor: 4.207

7.  The chemiluminescence based Ziplex automated workstation focus array reproduces ovarian cancer Affymetrix GeneChip expression profiles.

Authors:  Michael C J Quinn; Daniel J Wilson; Fiona Young; Adam A Dempsey; Suzanna L Arcand; Ashley H Birch; Paulina M Wojnarowicz; Diane Provencher; Anne-Marie Mes-Masson; David Englert; Patricia N Tonin
Journal:  J Transl Med       Date:  2009-07-06       Impact factor: 5.531

8.  Targeting the epidermal growth factor receptor in epithelial ovarian cancer: current knowledge and future challenges.

Authors:  Doris R Siwak; Mark Carey; Bryan T Hennessy; Catherine T Nguyen; Mollianne J McGahren Murray; Laura Nolden; Gordon B Mills
Journal:  J Oncol       Date:  2009-11-19       Impact factor: 4.375

Review 9.  New Predictive Biomarkers for Ovarian Cancer.

Authors:  Ghofraan Abdulsalam Atallah; Nor Haslinda Abd Aziz; Chew Kah Teik; Mohamad Nasir Shafiee; Nirmala Chandralega Kampan
Journal:  Diagnostics (Basel)       Date:  2021-03-07

10.  Assessment of the argyrophilic nucleolar organizer region area/nucleus ratio in ovarian serous epithelial adenomas, borderline tumors and cancers.

Authors:  Leszek Gottwald; Marian Danilewicz; Jacek Suzin; Malgorzata Wagrowska-Danilewicz; Michal Spych; Wieslaw Tylinski; Katarzyna Topczewska-Tylinska; Janusz Piekarski; Sylwia Kazmierczak-Lukaszewicz; Aleksandra Cialkowska-Rysz
Journal:  Arch Med Sci       Date:  2013-02-18       Impact factor: 3.318

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.